---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-23-000021"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:30:39.396022+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics eliminates President & CBO role, terminates David Slack effective May 1, 2023

## Summary
- Position of President and Chief Business Officer eliminated; David Slack terminated immediately.
- Slack resigned from Board of Directors per employment agreement.
- Severance: $478,400 over 12 months; bonus of $239,200 (50% of base salary) paid over same period.
- Additional lump sum of $24,134 for earned pay, PTO, and expenses; COBRA assistance provided.
- Vested option exercise period extended to three years post-termination or remaining term, whichever shorter.

## SEC filing metadata
- accession: 0000320017-23-000021
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/0000320017-23-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/clbs-20230501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-23-000021
- JSON: https://secwatch.observer/filing/0000320017-23-000021.json
- Plain text: https://secwatch.observer/filing/0000320017-23-000021.txt

## Key facts
- Executive change
  David Slack was terminated as President and Chief Business Officer at LISATA THERAPEUTICS, INC..
  - Action: terminated
  - Role: President and Chief Business Officer
  source text: On May 1, 2023, Lisata Therapeutics, Inc. (the “Company”), after a careful review of capital utilization and prioritization, eliminated the position of President and Chief Business Officer, and terminated the employment of Mr. David Slack, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/0000320017-23-000021-index.htm
- Executive change
  David Slack resigned as Director at LISATA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Director
  source text: Mr. Slack has effectively resigned from the Company’s Board of Directors as of May 1, 2023 pursuant to the terms of his Employment Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/0000320017-23-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.